![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Extension of Bulevirtide Monotherapy to 72 Weeks in HDV Patients with Compensated Cirrhosis: Efficacy and Safety From the Italian Multicenter Study (HEP4Di)
Interim Analysis
|
|
|
AASLD 2022 Nov 4-8 <
MP. Anolli1, E. Degasperi1, G. D'Offizi2, MR. Brunetto3, G. Verucchi4, A. Federico5, A. Ciancio6, A. Mangia7, TA. Santantonio8, N. Coppola9, A. Pellicelli10, A. Loglio11, M. Vigaṇ12, F. Pileri13, M. Maracci14, M. Puoti15, F. Piscaglia16 and P. Lampertico1,17
![1111221](../images/111122/111122-19/1111221.gif)
![1111222](../images/111122/111122-19/1111222.gif)
![1111223](../images/111122/111122-19/1111223.gif)
![1111224](../images/111122/111122-19/1111224.gif)
![1111225](../images/111122/111122-19/1111225.gif)
![1111226](../images/111122/111122-19/1111226.gif)
![1111227](../images/111122/111122-19/1111227.gif)
![1111228](../images/111122/111122-19/1111228.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|